Growth Factors

Thymosin Alpha-1

Evidence: strong_human

Mechanism of Action

Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.

Dosing Protocol

Standard: Research indicates 1.6 mg administered twice weekly via subcutaneous injection.

Loading: Research indicates 1.6 mg daily for 2 weeks during acute immune challenge, then transition to maintenance.

Maintenance: Research indicates 1.6 mg twice weekly for ongoing immune optimization.

Administration: subcutaneous

Timing: Morning administration preferred. No food timing restrictions.

Duration: 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.

Notes

Thymosin Alpha-1 is one of the few peptides in this database with robust human clinical data — it is approved in over 35 countries for hepatitis B/C and as an immune adjuvant. It has been studied extensively in cancer immunotherapy and was investigated during COVID-19. The compound has an excellent safety profile across clinical trials. Consider for immune optimization in HNW clients with frequent travel or infection exposure.

Stacking

  • BPC-157
  • GHK-Cu
  • Selank

Interactions

  • Immunosuppressants [HIGH] — Direct antagonism — Thymosin Alpha-1 enhances immune function, which may counteract immunosuppressive therapy.
  • Checkpoint inhibitors [HIGH] — Both enhance immune activation; combined use could increase autoimmune risk.
  • Interferons [MEDIUM] — Additive immune stimulation; monitor for overactivation.
  • May alter immunomodulatory therapy response

Contraindications

  • Organ transplant recipients on immunosuppression
  • Active autoimmune diseases
  • Pregnancy and breastfeeding
  • Autoimmune conditions require careful supervision

Side Effects

  • Injection site reactions
  • Mild flu-like symptoms
  • Fatigue
  • Muscle aches (rare)

Key Papers

  • 10.1016/bs.vh.2016.04.003
  • 10.1016/j.intimp.2023.111104
  • Clinical immunology literature on thymosin alpha-1

Source Quality

Pharmaceutical-grade (marketed as Zadaxin in multiple countries). Compounding pharmacy for US-based access.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Thymosin Alpha-1 Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds